{"organizations": [], "uuid": "5d96ec38f0411d6d5b6fd0e9722a2edcbdd338c3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180212.html", "section_title": "Archive News &amp; Video for Monday, 12 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-akebia-therapeutics-gives-update-o/brief-akebia-therapeutics-gives-update-on-vadadustat-development-program-idUSASB0C552", "country": "US", "domain_rank": 408, "title": "BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.309, "site_type": "news", "published": "2018-02-12T20:13:00.000+02:00", "replies_count": 0, "uuid": "5d96ec38f0411d6d5b6fd0e9722a2edcbdd338c3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-akebia-therapeutics-gives-update-o/brief-akebia-therapeutics-gives-update-on-vadadustat-development-program-idUSASB0C552", "ord_in_thread": 0, "title": "BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "vadadustat development program", "sentiment": "negative"}, {"name": "akebia therapeutics inc", "sentiment": "negative"}, {"name": "tect", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "mitsubishi tanabe pharma corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 12 (Reuters) - Akebia Therapeutics Inc:\n* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM\n* AKEBIA THERAPEUTICS INC - TARGETS FULL ENROLLMENT FOR INNO(2)VATE AND PRO(2)TECT BY END OF 2018\n* AKEBIA THERAPEUTICS INC - CONFIRMS EXPECTATION OF TOP-LINE RESULTS FOR INNO(2)VATE & PRO(2)TECT IN 2019, SUBJECT TO ACCRUAL OF MACE EVENTS\n* AKEBIA THERAPEUTICS INC - PARTNER MITSUBISHI TANABE PHARMA CORP INITIATES PHASE 3 NDD-CKD AND DD-CKD PROGRAM IN JAPAN Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-12T20:13:00.000+02:00", "crawled": "2018-02-13T15:28:21.014+02:00", "highlightTitle": ""}